Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 5/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949039 | 0.89 | SIGMAR1 (0.53) | GAASMN1; SMN2PARP1SIGMAR1PKM | |
| SCHEMBL7949425 | 0.87 | LMNA (0.52) | GAASMN1; SMN2PARP1SIGMAR1PKM | |
| SCHEMBL7959347 | 0.85 | LMNA (0.45) | GAASMN1; SMN2PARP1HTR7SIGMAR1 | |
| SCHEMBL7960931 | 0.85 | SIGMAR1 (0.56) | PARP1SIGMAR1POLBHPGD | |
| SCHEMBL7964099 | 0.84 | HPGD (0.53) | PARP1SIGMAR1POLBHPGD | |
| SCHEMBL7960974 | 0.83 | LMNA (0.45) | GAASMN1; SMN2PARP1SIGMAR1PKM | |
| SCHEMBL7958937 | 0.83 | PKM (0.52) | GAASMN1; SMN2PARP1SIGMAR1PKM | |
| SCHEMBL7957285 | 0.83 | SIGMAR1 (0.53) | PARP1SIGMAR1POLB | |
| SCHEMBL7959188 | 0.83 | HPGD (0.51) | GAASIGMAR1POLBHPGD | |
| SCHEMBL7959202 | 0.83 | GAA (0.41) | GAASMN1; SMN2PARP1SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |